TAKEDA PHARMACEUTICAL CO LTD (TAK)
Pharmaceutical Preparations · market cap $60.2B · as of 2026-10-16
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-11-30 (est.)Phase 2 · TAK-360imp 7/10
- 2026-12-15 (est.)Phase 2 · Ixazomibimp 7/10
- 2027-01-15 (est.)Phase 2 · FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)imp 7/10
- 2027-01-18 (est.)Phase 3 · Maribavirimp 9/10
- 2027-02-05 (est.)Phase 2 · Zasocitinib (Dose A)imp 7/10
- 2027-02-10 (est.)Phase 3 · Teduglutideimp 9/10
- 2027-02-17 (est.)Phase 2 · TAK-279imp 7/10
- 2027-03-15 (est.)Phase 2 · C1 Esterase Inhibitor Injectionimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| REPLAGAL | Phase 3 | Fabry Disease |
| IGSC | Phase 3 | Primary Immunodeficiency Disease |
| Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus |
| B-MAD chemotherapy | Phase 2 | Extranodal NK/T-cell Lymphoma |
| HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) |
| Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever |
| Leuprorelin acetate | Phase 2 | Endometriosis |
| Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications | Phase 3 | Hypertension |
| FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Phase 2 | Colon Cancer |
| Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia |
| Glyburide | Phase 3 | Diabetes Mellitus |
| Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia |
| Azilsartan medoxomil with or without add-on hydrochlorothiazide | Phase 3 | Hypertension |
| HCTZ | Phase 3 | Essential Hypertension |
| TAK-536CCB tablet | Phase 3 | Essential Hypertension |
| Colchicine | Phase 3 | Atrial Fibrillation |
| Vedolizumab | Phase 3 | Colitis, Ulcerative |
| TAK-861 | Phase 3 | Narcolepsy Type 1 |
| Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension |
| Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for TAK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
